Finance

Lists
Outlook: 44.4% bullish·0.0% bearish
Go to analysis
VEEV:NYSE
Veeva Systems Inc
$297.35
-1.42%
(-4.28) 1D
$296.00
-0.45% (-1.35)
Pre-market
Closed: Oct 14, 4:00:06 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VEEV...
Open
$300.14
High
$301.50
Low
$293.66
Mkt. cap
48.14B
Avg. vol.
1.47M
Volume
833.00
P/E ratio
48.63
52-wk high
$309.32
52-wk low
$148.05
EPS
$6.11
Beta
0.93
Shares outstanding
161.91M
No. of employees
8K
Open
$300.14
High
$301.50
Low
$293.66
Mkt. cap
48.14B
Avg. vol.
1.47M
Volume
833.00
P/E ratio
48.63
52-wk high
$309.32
52-wk low
$148.05
EPS
$6.11
Beta
0.93
Shares outstanding
161.91M
No. of employees
8K
News stories
From web sources and news partners
Profile
Veeva Systems Inc., headquartered in Pleasanton, California, provides cloud computing software, data, and consulting services for the life sciences industry. Its products are used to track all aspects of drug development and pharmaceutical manufacturing. The company has 1,552 customers including Bayer, Boehringer Ingelheim, Eli Lilly and Company, Gilead Sciences, Merck & Co., Novartis, Alkermes plc, Alnylam Pharmaceuticals, bluebird bio, and Idorsia. Wikipedia
About Veeva Systems Inc
CEOPeter Gassner
Employees7.93K
Founded2007
HeadquartersPleasanton, California, United States
SectorHealth care
Websiteveeva.com
Analyst ratings
Based on 24 analysts giving stock ratings to VEEV in the past 3 months
Buy
Buy
17
Hold
6
Sell
1
12-month forecast
Based on 24 Wall Street analysts offering 12 month price targets for VEEV in the last 3 months.
Highest
Current $297.35
$340.00 (+14.34%)
Average
$293.57 (-1.27%)
Lowest
$180.00 (-39.47%)
Analyst
Recommendation
Action
Price target
Projected
Date
Joseph Vruwink
Robert W. Baird
Buy
Maintained
$300.00
+0.9%
10/09/2026
Stan Berenshteyn
Wells Fargo
Buy
Maintained
$330.00
+11%
09/30/2026
Craig Hettenbach
Morgan Stanley
Hold
Reiterated
$275.00
-7.5%
09/18/2026
Unknown Analyst
CFRA
Buy
Upgraded
-
-
09/16/2026
Charles Rhyee
TD Cowen
Buy
Reiterated
$283.00
-4.8%
09/15/2026
Alexei Gogolev
J.P. Morgan
Buy
Maintained
$299.00
+0.6%
09/01/2026
Tyler Radke
Citi
Hold
Maintained
$273.00
-8.2%
08/28/2026
Brian Peterson
Raymond James
Buy
Maintained
$330.00
+11%
08/27/2026
Kenneth Wong
Oppenheimer
Buy
Reiterated
$325.00
+9.3%
08/27/2026
Gabriela Borges
Goldman Sachs
Sell
Maintained
$180.00
-39.5%
08/26/2026
Kirk Materne
Evercore ISI
Hold
Maintained
$250.00
-15.9%
08/27/2026
Rishi Jaluria
RBC Capital
Buy
Maintained
$325.00
+9.3%
08/26/2026
Sean Dodge
BMO Capital
Hold
Reiterated
$270.00
-9.2%
08/27/2026
David Larsen
BTIG
Buy
Maintained
$340.00
+14.3%
08/26/2026
Steven Valiquette
Mizuho Securities
Buy
Maintained
$280.00
-5.8%
08/27/2026
Karl Keirstead
UBS
Hold
Reiterated
$290.00
-2.5%
08/28/2026
Ryan MacDonald
Needham
Buy
Reiterated
$310.00
+4.3%
08/27/2026
David Hynes
Canaccord Genuity
Hold
Maintained
$260.00
-12.6%
08/27/2026
Tamjid Chowdhury
Guggenheim
Buy
Maintained
$310.00
+4.3%
08/27/2026
David Grossman
Stifel Nicolaus
Buy
Maintained
$300.00
+0.9%
08/27/2026
Billy Fitzsimmons
Piper Sandler
Buy
Maintained
$320.00
+7.6%
08/27/2026
Dylan Becker
William Blair
Buy
Maintained
-
-
08/27/2026
Jailendra Singh
Truist Financial
Buy
Maintained
-
-
08/26/2026
Saket Kalia
Barclays
Buy
Maintained
$315.00
+5.9%
08/27/2026
John Difucci
Guggenheim
Buy
Initiated
$232.00
-22%
07/22/2026
Unknown Analyst
Guggenheim
Buy
Initiated
$232.00
-22%
07/22/2026
Martin Yang
Oppenheimer
Buy
Reiterated
$225.00
-24.3%
06/04/2026
Hannah Rudoff
Piper Sandler
Buy
Maintained
$235.00
-21%
06/04/2026
Adam Hotchkiss
Goldman Sachs
Sell
Maintained
$165.00
-44.5%
06/04/2026
Unknown Analyst
Stephens
Buy
Maintained
$324.00
+9%
03/05/2026
Bradley Sills
Bank of America Securities
Hold
Maintained
$304.00
+2.2%
03/04/2026
Last report
Aug 26, 2026
Fiscal period
Q2 2027
$2.35 / $2.22
+5.77%beat
Revenue / Est. (USD)
927.96M / 905.26M
+2.51%beat
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Oct 2025
Jan 2026
Apr 2026
Jul 2026
Revenue
811.24M
835.95M
882.95M
927.96M
Cost of goods sold
199.46M
213.48M
220.92M
232.01M
Cost of revenue
199.46M
213.48M
220.92M
232.01M
Research and development expenses
191.88M
198.79M
208.32M
222.92M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
179.04M
177.80M
180.59M
198.02M
Operating expense
370.92M
376.60M
388.91M
420.93M
Total operating expenses
570.38M
590.08M
609.84M
652.94M
Operating income
240.85M
245.88M
273.11M
275.02M
Other non operating income
-
934.00K
-
-
EBT including unusual items
312.79M
317.54M
347.53M
349.53M
EBT excluding unusual items
312.79M
315.70M
345.74M
349.53M
Income tax expense
76.58M
73.33M
86.59M
76.10M
Effective tax rate
24.48%
23.09%
24.92%
21.77%
Other operating expenses
-
-
-
-
Net income
236.20M
244.20M
260.94M
273.43M
Net profit margin
29.12%
29.21%
29.55%
29.47%
Earnings per share
2.04
2.06
2.24
2.35
Interest and investment income
71.93M
74.35M
70.63M
72.51M
Interest expense
-
-
-
-
Net interest expenses
71.93M
74.35M
70.63M
72.51M
Depreciation and amortization charges
-
-
-
-
EBITDA
250.56M
254.19M
284.70M
285.89M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps